Who are late leukostim's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Neulasta, Neupogen, early leukostim, PEG-G-CSF, Pegylated rhG-CSF regimen, LENOGRASTIM (GRANOGYTE 34).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/late-leukostim.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

late leukostim — Competitive Intelligence Brief

late leukostim (late leukostim) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Growth factor. Area: Oncology.

marketed Growth factor G-CSF receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

late leukostim (late leukostim) — Hyuk moon Kim. Late leukostim stimulates the proliferation of hematopoietic progenitor cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
late leukostim TARGET	late leukostim	Hyuk moon Kim	marketed	Growth factor	G-CSF receptor
Neulasta	Pegfilgrastim-Apgf	Amgen	marketed	Colony-stimulating factor	G-CSF receptor on hematopoietic cells	2002-01-01
Neupogen	Filgrastim-Aafi	Amgen	marketed	Colony-stimulating factor (CSF); leukocyte growth factor	G-CSF receptor (granulocyte colony-stimulating factor receptor)	1991-01-01
early leukostim	early leukostim	Hyuk moon Kim	marketed	Growth factor	G-CSF receptor
PEG-G-CSF	PEG-G-CSF	Sanofi	marketed	Granulocyte colony-stimulating factor (G-CSF) analog	G-CSF receptor (GCSFR)
Pegylated rhG-CSF regimen	Pegylated rhG-CSF regimen	Shandong Provincial Hospital	marketed	G-CSF receptor agonist	G-CSF receptor (CSF3R)
LENOGRASTIM (GRANOGYTE 34)	LENOGRASTIM (GRANOGYTE 34)	Sanofi	marketed	Granulocyte colony-stimulating factor (G-CSF)	G-CSF receptor (GCSFR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Growth factor class)

Chinese PLA General Hospital · 2 drugs in this class
Hyuk moon Kim · 2 drugs in this class
Centre Oscar Lambret · 1 drug in this class
Genzyme, a Sanofi Company · 1 drug in this class
SVS Institute of Dental Sciences · 1 drug in this class
Soligenix · 1 drug in this class
Xiamen Amoytop Biotech Co., Ltd. · 1 drug in this class
Adocia · 1 drug in this class
Zensun Sci. & Tech. Co., Ltd. · 1 drug in this class
Australasian Gastro-Intestinal Trials Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). late leukostim — Competitive Intelligence Brief. https://druglandscape.com/ci/late-leukostim. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab